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The clinical success of perispinal administration of opiates for pain relief has
demonstrated the power ofmanipulating the neurochemistry ofthe spinal cord.
This articlebriefly discussed reasons for increased interest in new spinal agents
and some ofthe issues associated withdetermining their clinical safety.
When considering toxicity ofnew agents that are likely to be applied near the spinal
cord, that is, by the perispinal route ofadministration, we mustmake the following gener-
al assumption: any new agent administered by the perispinal route, atconcentrations ade-
quate to produce the desired pharmacologic effect, must be assumed to be toxic to the
spinal cord. This assumption must be made even ifthe agent has been demonstrated to be
safe when administered systemically in humans. Although this assumption is likely to be
proven wrong in most instances, the devastating impact of spinal cord trauma as a result
ofdrug administration by the perispinal route demands that we have solid evidence ofthe
absence ofspinal toxicity before new agents are administered by thatroute.
Why do we neednewspinalagents?
While some may question the need for new agents to be administered perispinally,
there are at least three factors that are likely to contribute to increased efforts to modify
the local pharmacology of the spinal cord. These efforts are likely to involve substances
in which spinal safety has not been demonstrated. Until Yaksh and Rudy [1] demonstrat-
ed the behavioral analgesic effects ofthe direct spinal action ofnarcotics, the spinal cord
was thought of by many as a simple cable. Although it was clear that local anesthetics
could act to block sensory and motor activity within the spinal cord, little attention was
given to the clinical importance of the pharmacology of spinal sensory processing.
Documentation ofthe directaction ofopiates on spinal sensory processing [2, 3, 4] led to
the behavioral work by Yaksh and Rudy and revealed thepotential importance ofa better
understanding of how the nervous system communicates within the spinal dorsal horn. It
is now obvious that the pharmacology of spinal sensory processing provides unique
opportunities to influence sensory experience.
The first reason for the use of new spinal agents is our increasing understanding of
the complexity ofthe pharmacology ofspinal sensory processing. Ifwe focus only on C-
fibers that are associated with transmission ofinformation about noxious mechanical and
thermal stimuli in the periphery, the complexity of the system is quickly apparent. There
are at the least seven neurotransmitters that are likely to be released by those C-fibers
(glutamate, aspartate, substanceP, neurokinin A, neurokinin B, CGRP, and somatostatin).
The presynaptic terminal ofthe C-fibers, in addition to releasing those neurotransmitters,
also contains a series of receptors that may be acted upon by opioid, alpha adrenergic,
GABA, cholecystokinin, serotonin, and excitatory amino acid neurotransmitters.
Activation of some of those receptors will enhance the transmission ofinformation from
primary afferents to second orderneurons. Mostare likely to depress thattransmission.
aTo whom all correspondence should be addressed. 333 Cedar Street, P. 0. Box 208051, New
Haven, Connecticut 06520-8051.
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The second order neurons that will receive the message from the C-fibers also have a
large number of receptors, the activation of which may modify their response to the
incoming message. Activation of excitatory amino acid AMPA, NMDA; neuroKinin
NK1, NK2, NK3; opiate mu, delta, kappa; alpha2 adrenergic; gamma aminobutyric acid
GABAA, GABAB; serotonin, 5HT1, 5HT3; or cholecystokinin CCKA, CCKB receptors on
the second order neurons may either enhance or depress the transmission of information
from the C-fibers. Neurotransmitters that may produce physiological effects at those sites
could be released by interneurons, descending modulatory systems orotherprimary affer-
ents. The above mentioned relationships recently have been summarized graphically by
Dickenson [5].
The above very brief description of interactions that are likely to occur at the first
synapse between a primary afferent carrying information about pain and second order
neurons demonstrates the extremely rich pharmacology that appears to be involved in the
normal transmission of information about pain. For the basic scientist, this rich interac-
tion of receptors and neurotransmitters provides a fascinating research tool; for the clini-
cian, it provides unique opportunities for drug interactions and the possibility of
enhanced pain control by the appropriate use of drug combinations administered by the
perispinal route.
It is important to recognize that the normal transmission ofinformation in the spinal
dorsal horn is assumed to be depend upon interactions among many of the above men-
tioned transmitter systems. It is also likely that the most effective pharmacological inter-
ventions may result from drug combinations rather than a single agent. This is especially
true if synergistic interactions seen in animal studies [6] are also present in the clinical
setting.
While some may argue that new agents or combinations are not needed for the man-
agement of acute postoperative pain, it is clear that difficult to manage chronic pain may
come under better control if such strategies are made available. We must, therefore,
assume that one of the driving forces behind the use ofnew spinal agents will be an effort
to provide better analgesia by perispinal drug administration.
A second reason for a continuing evaluation of possible new perispinal drugs relates
to the significant plasticity that has been demonstrated in the spinal dorsal horn and the
possible role that such plasticity plays in some chronic pain states. This plasticity is evi-
dent in many ways. Clinically, it has been best demonstrated in a study from Campbell's
group [7] in which they reported that, in some patients, activity in large myelinated fibers
is responsible for the transmission of information that is ultimately interpreted as pain.
The hyperalgesia associated with nerve injury in those patients was clearly signalled by
A-beta fibers, fibers that normally would not be associated with signaling pain. An inter-
pretation of those findings is that the nerve damage caused a change in the way that the
central nervous system processed information. That plasticity may be a cause of some
chronic pain states.
Plasticity is likely to play an important role in some forms ofchronic pain. The plas-
ticity, itself, although anatomical in some instances, is likely in a large number ofcases to
be the result ofchanges in the neurochemistry of sensory transmission at the spinal level.
[8]. Efforts to "correct" plasticity associated with chronic pain will be an additional driv-
ing force behind the testing ofnew spinal agents.
The third reason for new spinal agents, and one that is often overlooked, relates to
spinal cord trauma. There is now excellent evidence to suggest that very early interven-
tion is likely to reduce the amount of damage resulting from spinal cord trauma.[9].
Spinal cord trauma may result in both loss of function as well as both acute and chronic
pain. In addition to the effects of mechanical trauma, it is now clear that resulting
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derangements in neurochemistry contribute to the overall level of trauma [10]. As we
begin to better understand the neuropharmacology of spinal cord trauma, it is likely that
drug intervention by the perispinal route may provide an opportunity for better clinical
outcome.
How do we decide ifnewspinalagentsare safe?
Ifwe assume that new agents are to be administered by the perispinal route, we then
need to consider how we are to know that these new agents are safe. As reviewed recent-
ly at a satellite meeting to the Seventh World Congress on Paina, Gordh, Eisenach, and
Yaksh discussed a numberofissues thatneed to be dealtwith when weconsidersafety of
perispinal drug administration. A number of those issues are relevant to this presentation
and are discussed below.
Preclinical animalstudies
First and foremost, animal studies are required. The purpose of these animal studies
is to define the maximum dose that does not cause toxicity. We must assume that toxicity
will be proportional to the local concentration of the agent or agents and the duration of
exposure to them.
An extremely important aspect of these tests and one that unfortunately is frequently
left out is a positive control. In situations in which knowledge of the drug under study
provides some sense ofwhat the acute toxicity may be, it is essential that a positive con-
trol be included to guarantee that the test system is sensitive enough to be able to demon-
strate the presence ofthe expected toxicity.
At the very least, three separate pieces of information should be obtained from ani-
mal studies. The first relates to behavioral pathology. Dose ranging from the subtoxic to
the toxic needs to be employed in order to determine what behavioral changes are likely
to beproducedby theperispinaladministration ofthe agentunderstudy.
The second area ofinterest, and one that is frequently not attended to, is spinal cord
blood flow. This is especially important since it is likely that combinations ofagents will
be administered perispinally. An individual agent may reduce spinal cord blood flow
without producing adverse effects but when combined with another agent that same
reduction in blood flow may be toxic. It is, therefore, important to examine the effects of
new agents and combinations on spinal blood flow.
The final area of interest would be tissue pathology. Here again, appropriate dosing
and duration of exposure will need to be studied to determine what, if any, pathological
changes are likely to occur within the spinal cord as a result ofperispinal administration
ofthe agentunderstudy.
In addition to the above three major points of interest in animal studies, there are a
large number of independent factors that need to be considered when evaluating the
spinal toxicity of new agents. Clearly, the route ofadministration is ofimportance. There
may be significantdifferences between epidural and intrathecal drug administration espe-
cially depending upon the lipophilicity of the particular agent. A drug of high
lipophilicity is likely to be cleared rapidly from the perispinal space, whereas a drug of
lower lipophilicity may remain longer. We assume that a drug remaining in the space for
a longer period of time may have a greater opportunity to produce toxicity. This is an
important consideration when we are examining agents that are likely to be administered
over long periods of time and raises challenging basic science questions about exactly
how long the exposure of a particular drug should be in order to be able to adequately
aAlpha2Adrenergic Mechanisms in Spinal Analgesia, Luceme, Switzerland, August, 1993.
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assess possible toxicity.
Our purpose is to try to define the worstpossible situations that are likely to occur in
the human. Therefore, if one is considering differences between epidural and intrathecal
administration, one should assume that the intrathecal injection is likely to be the most
damaging and therefore it should be evaluated in the animal since the highest local con-
centration near the spinal cord maybeachievedby thatroute.
While the purpose ofthe animal studies is to define the maximum dose thatdoes not
cause acute toxicity, we are always limited by the realization that there may be toxicities
that have notbeen identifiedbecause the doses have notbeen taken to ahigherlevel, (i.e.,
Has the maximum dosingrange been used?). It may not be possible to define a maximum
dose range, but the pharmacology of the agent under study may be provide some indica-
tion of expected side effects. In those situations those side effects may be defined as the
limiting factors in the dose ranging so that there is a rationale behind the choice ofapar-
ticular maximum dose range.
Clinical studies
Having defined the maximum dose thatdoes notcause toxicity in animal studies, itis
now time to pursue information about the possible toxicity ofthe agent in humans. These
studies, which have been referred to as Phase I studies, have a single purpose. That pur-
pose is to define the safety and side effects ofthe agent. Although information about effi-
cacy may be obtained in Phase I trials theironly purpose is to examine safety. Becauseof
the nature of the experiment, the study is open labeled and would be expected to employ
a dose range from subtherapeutic levels to concentrations where limiting side effects
would be observed. Of particular importance here, the preclinical animal work should
have hinted at the side effects and prior to initiation of these studies there needs to be a
plan in place to respond to expected side effects.
An unresolved question focuses on the most appropriate individuals to be included in
a Phase I study. Three choices are typically used: terminally ill patients who may derive
some benefit from the treatment, patients with medical problems that could benefit from
the treatment, and volunteers who, beyond the financial reward for participation in the
tests, will derive no benefit from the treatment. There are positive and negative scientific
and ethical issues associated with choosing the patient population for Phase I trials. We
need to be concerned with the coercive effectofmoney ifvolunteers are employed. Non-
terminal patients may feel forced to participate because of the trust they place in their
doctors. When determining thepatientpopulation thatis tobe used, we need toremember
that the purpose ofPhase I trials is not to determine efficacy. It is only to determine the
safety and side effects ofthe agents.
Phase II testing provides an opportunity, in a small number of patients, to begin to
define the efficacy ofthe agents under study. It is important thatPhase II studiesbeblind-
ed. Finally, Phase III studies, which will include larger numbers ofpatients, will focus on
both efficacy and the safety and therefore will require placebo controlled studies wherev-
er possible.
Although theperispinal administration ofopiates for thereliefofpain is now a wide-
ly accepted technique, the developmentofthat technique does notprovide thebest exam-
ple of how toxicity studies should be conducted. The model that this author feels should
be followed in an evaluation ofsafety and efficacy of new agents for spinal administra-
tion is provided by work done in evaluating alpha adrenergic agonists. Gordh [11-13]
Eisenach [14-18] andcolleagues, working independently, haveprovided us with a wealth
ofinformation about the safety andefficacy ofthe spinal administration ofalphaadrener-
gic agonists for the reliefofpain. Their workprovides an ideal model for anyone interest-
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ed in testing of additional agents for the perispinal administration of drugs. While the
work is demanding, and the results are not immediately available to the clinical world, as
indicated at the outset, we mustassume that any new agent at aconcentration adequate to
produce analgesia will be toxic to the spinal cord ifadministeredby the spinal route.
Unfortunately, many substances have been administered to humans by the spinal
route in small clinical studies that have demonstrated neither safety nor efficacy. As we
look at those studies, we need to recognize that there are least three major flaws in their
usage and although they may continue to appear in the literature we must be adamant in
insisting that they not be considered as the acceptable way of demonstrating the lack of
toxicity of new agents for administration of the perispinal route. Typically, these small
clinical studies have sample size that is extremely limited. Secondly, the studies are typi-
cally notdesigned to demonstrate safety butrather are an attempt to show thatone or two
limited doses ofthe drugs produce a desired effect. These results however are frequently
obtained in the absence of blinded controls. Perhaps most importantly the studies rarely
employ follow up in order to determine both short term and long term toxicities that may
be associated with these drugs.
The pharmacology of spinal sensory processing is an extremely complex area. The
complexity provides both a level offrustration as we attempt to understand how it works
but also a unique series ofopportunities to betterregulate various derangements in senso-
ry processing that are seen in the clinical setting. It is our responsibility to make sure that
the testing ofnew agents forperispinal administration is carried outin a scientific fashion
that will demonstrate clearly both the lack of toxicity and the efficacy of an individual
agentprior to its widespread usageclinically.
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